| Abstrakt: |
Antineoplastics, Biotechnology, Cancer, Decitabine Therapy, Drugs and Therapies, Health and Medicine, Hematology, Immunologic Agents, Immunotherapy, Ipilimumab Therapy, Leukemia, Monoclonal Antibodies, Oncology, Pharmaceuticals, Yervoy Therapy, Antimetabolites Keywords: Antimetabolites; Antineoplastics; Biotechnology; Cancer; Decitabine Therapy; Drugs and Therapies; Health and Medicine; Hematology; Immunologic Agents; Immunotherapy; Ipilimumab Therapy; Leukemia; Monoclonal Antibodies; Oncology; Pharmaceuticals; Yervoy Therapy EN Antimetabolites Antineoplastics Biotechnology Cancer Decitabine Therapy Drugs and Therapies Health and Medicine Hematology Immunologic Agents Immunotherapy Ipilimumab Therapy Leukemia Monoclonal Antibodies Oncology Pharmaceuticals Yervoy Therapy A new study on leukemia is now available. Evidence of immune activation was only apparent following ipilimumab exposure, which altered CD4+ T cell gene expression, in line with ongoing T cell differentiation and increased frequency of marrow-infiltrating regulatory T cells. [Extracted from the article] |
